Home › NCT05675527

PRP for Glenohumeral Osteoarthritis

Outcomes Following Single Injections of Low-dose Platelet-rich Plasma (PRP), High-dose PRP, or Saline in Patients With Glenohumeral OA: a Randomized Controlled Trial

Who can join

Ages 18 to 100 · All sexes

Inclusion Criteria:

* 18-100 years old
* Average NRS pain greater than or equal to 5/10 as a direct result of glenohumeral osteoarthritis (any severity: mild, moderate, or severe) and/or chondral lesion or loss
* At least 3 months of pain after onset of symptoms that has failed conservative treatments, including physical therapy
* MRI of the affected joint
* Transient relief of symptoms after a diagnostic intra-articular injection into the joint
* Email address or network access

Exclusion Criteria:

* Inability to hold non-steroidal anti-inflammatory drugs for 2 weeks prior and 1 month after the injection
* Prior platelet-rich plasma injection
* Steroid injection within 3 months of the initial injection
* Hyaluronic acid within 6 months of the initial injection
* Involved in workers' compensation or active litigation involving the affected joint
* History of Plavix use
* Known uncontrolled systemic illness (uncontrolled diabetes, HIV, vasculitis, autoimmune/autoinflammatory disease)
* Presence of acute fractures or gross mechanical deformities
* Concurrent "uncontrolled" cervical disorders

About the study

The glenohumeral joint is the third most common large joint to be affected by OA. Conservative treatments include physical activity, corticosteroid injections, and medications. PRP is an emerging treatment that has shown efficacy in different musculoskeletal conditions. The use of PRP for glenohumeral OA has been described sparingly in the literature but has shown efficacy in a couple studies and case reports. However, all of the previous studies investigating PRP for glenohumeral OA have focused on low-dose PRP preparations (\~3X), and none have compared PRP treatment to saline treatment. This study aims to compare outcomes following single injections of low-dose PRP, high-dose PRP, or saline in patients with glenohumeral osteoarthritis.

What is being tested

• Low-dose PRP (biological)
• High-dose PRP (biological)
• Saline (other)

Sponsor: Hospital for Special Surgery, New York · Participants: 135 · Started: May 2, 2023

Contact the study team

• Jonathan Kirschner, MD · Phone: 646-714-6327
• Jennifer Cheng · Phone: 646-714-6870

Official record on ClinicalTrials.gov — NCT05675527

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.